Director at Evolus (EOLS) awarded 45,559 restricted stock units

Rhea-AI Filing Summary

White Albert G III reported acquisition or exercise transactions in this Form 4 filing.

Evolus, Inc. director Albert G. White III received an equity award of 45,559 shares of common stock in the form of restricted stock units (RSUs) on February 17, 2026. The award was granted at no cash cost per share and is a stock-based compensation grant, not an open-market purchase.

Each RSU represents a contingent right to receive one Evolus common share and will vest in full on “the one year anniversary of February 17, 2026,” if he remains in continuous service, with potential accelerated vesting upon certain changes of control. Following this grant, his reported direct holdings total 95,937 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider White Albert G III

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	45,559	$0.00	--

Holdings After Transaction: Common Stock — 95,937 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

White Albert G III

(Last) (First) (Middle)

520 NEWPORT CENTER DRIVE

SUITE 1200

(Street)

NEWPORT BEACH CA 92660

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Evolus, Inc. [ EOLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		45,559(1)	A	$0	95,937	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 17, 2026, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer.

Remarks:

	/s/ Jeffrey J. Plumer, as attorney-in-fact for Albert G. White III	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Evolus (EOLS) report for Albert G. White III?

Evolus reported that director Albert G. White III received a grant of 45,559 restricted stock units. These RSUs are stock-based compensation, issued at no cash cost, and increase his reported direct holdings to 95,937 shares of Evolus common stock.

How many Evolus (EOLS) shares were granted in the latest Form 4 filing?

The Form 4 filing shows a grant of 45,559 restricted stock units, each representing one Evolus common share. The grant increased the director’s total direct holdings to 95,937 common shares, reflecting an equity compensation award rather than an open-market transaction.

What are the vesting terms of the new Evolus (EOLS) RSU grant?

The 45,559 RSUs will vest in full on "the one year anniversary of February 17, 2026," if the director remains in continuous service. The award is also subject to accelerated vesting in certain events, including specified changes of control of Evolus.

Is the Evolus (EOLS) Form 4 transaction a stock purchase by the director?

No, the Form 4 transaction is a grant of restricted stock units, not an open-market stock purchase. The RSUs were awarded at a stated price of $0.0000 per share as equity compensation, contingent on future vesting conditions and continued service.

How did the RSU grant affect Albert G. White III’s Evolus (EOLS) holdings?

After receiving 45,559 RSUs, the director’s reported direct holdings increased to 95,937 shares of Evolus common stock. These holdings include the newly granted RSUs, which convert into shares only upon satisfying the stated vesting conditions and timelines.

What potential acceleration features apply to the Evolus (EOLS) RSUs?

The RSUs are subject to accelerated vesting in certain events, including upon specified changes of control of Evolus. This means the units could vest earlier than the one-year anniversary of February 17, 2026, if those defined corporate events occur.